BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Tag: Gelsolin

Dataset: Transcription profiling of human estrogen receptor postive breast cancer samples treated with tamoxifen to predict prognosis

Background: Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to their clinical behavior and response to...

Registered by ArrayExpress Uploader
View Dataset

Background: Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to their clinical behavior and response to therapies. The ER is currently the best predictor of response to the anti-estrogen agent tamoxifen, yet up to 30-40% of ER+BC will relapse despite tamoxifen treatment. New prognostic biomarkers and further biological understanding of tamoxifen resistance are required. We used gene expression profiling to develop an outcome-based predictor using a training set of 255 ER+ BC samples from women treated with adjuvant tamoxifen monotherapy. We used clusters of highly correlated genes to develop our predictor to facilitate both signature stability and biological interpretation. Independent validation was performed using 362 tamoxifen-treated ER+ BC samples obtained from multiple institutions and treated with tamoxifen only in the adjuvant and metastatic settings. Results: We developed a gene classifier consisting of 181 genes belonging to 13 biological clusters. In the independent set of adjuvantly-treated samples, it was able to define two distinct prognostic groups (HR 2.01 95%CI: 1.29-3.13; p=0.002). Six of the 13 gene clusters represented pathways involved in cell cycle and proliferation. In 112 metastatic breast cancer patients treated with tamoxifen, one of the classifier components suggesting a cellular inflammatory mechanism was significantly predictive of response. Conclusions: We have developed a gene classifier that can predict clinical outcome in tamoxifen-treated ER+ BC patients. Whilst our study emphasizes the important role of proliferation genes in prognosis, our approach proposes other genes and pathways that may elucidate further mechanisms that influence clinical outcome and prediction of response to tamoxifen. Experiment Overall Design: dataset of microarray experiments from primary breast tumors of patients treated by Tamoxifen in adjuvant setting. No replicate, no reference sample.

Species:
human

Samples:
77

Source:
E-GEOD-9195

Updated:
Dec.12, 2014

Registered:
Sep.22, 2014


Factors: (via ArrayExpress)
Sample
GSE9195GSM232194
GSE9195GSM232195
GSE9195GSM232196
GSE9195GSM232197
GSE9195GSM232198
GSE9195GSM232199
GSE9195GSM232200
GSE9195GSM232201
GSE9195GSM232202
GSE9195GSM232203
GSE9195GSM232204
GSE9195GSM232205
GSE9195GSM232206
GSE9195GSM232207
GSE9195GSM232208
GSE9195GSM232209
GSE9195GSM232210
GSE9195GSM232211
GSE9195GSM232212
GSE9195GSM232213
GSE9195GSM232214
GSE9195GSM232215
GSE9195GSM232216
GSE9195GSM232217
GSE9195GSM232218
GSE9195GSM232219
GSE9195GSM232220
GSE9195GSM232221
GSE9195GSM232222
GSE9195GSM232223
GSE9195GSM232224
GSE9195GSM232225
GSE9195GSM232226
GSE9195GSM232227
GSE9195GSM232228
GSE9195GSM232229
GSE9195GSM232230
GSE9195GSM232231
GSE9195GSM232232
GSE9195GSM232233
GSE9195GSM232234
GSE9195GSM232235
GSE9195GSM232236
GSE9195GSM232237
GSE9195GSM232238
GSE9195GSM232239
GSE9195GSM232240
GSE9195GSM232241
GSE9195GSM232242
GSE9195GSM232243
GSE9195GSM232244
GSE9195GSM232245
GSE9195GSM232246
GSE9195GSM232247
GSE9195GSM232248
GSE9195GSM232249
GSE9195GSM232250
GSE9195GSM232251
GSE9195GSM232252
GSE9195GSM232253
GSE9195GSM232254
GSE9195GSM232255
GSE9195GSM232256
GSE9195GSM232257
GSE9195GSM232258
GSE9195GSM232259
GSE9195GSM232260
GSE9195GSM232261
GSE9195GSM232262
GSE9195GSM232263
GSE9195GSM232264
GSE9195GSM232265
GSE9195GSM232266
GSE9195GSM232267
GSE9195GSM232268
GSE9195GSM232269
GSE9195GSM232270

Tags

  • breast
  • breast cancer
  • cancer
  • cell
  • estrogen

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2025 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use